Published in AIDS Weekly, November 15th, 1999
C. Raskino and colleagues compared the impact of three different nucleoside reverse transcriptase inhibitor regimens - zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy - on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV) infected children.
They reported their findings in a recent issue of the journal Pediatrics ("Neurologic, Neurocognitive, and Brain Growth Outcomes in Human Immunodeficiency Virus-Infected Children...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.